Seer, Inc. Class A Common Stock earnings per share and revenue
On Nov 06, 2025, SEER reported earnings of -0.32 USD per share (EPS) for Q3 25, missing the estimate of -0.30 USD, resulting in a -4.58% surprise. Revenue reached 4.12 million, compared to an expected 4.08 million, with a 1.00% difference. The market reacted with a -3.24% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.32 USD, with revenue projected to reach 4.69 million USD, implying an increase of 0.00% EPS, and increase of 13.86% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Seer, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Seer, Inc. Class A Common Stock reported EPS of -$0.32, missing estimates by -4.58%, and revenue of $4.12M, 1% above expectations.
How did the market react to Seer, Inc. Class A Common Stock's Q3 2025 earnings?
The stock price moved down -3.24%, changed from $2.16 before the earnings release to $2.09 the day after.
When is Seer, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Feb 26, 2026.
What are the forecasts for Seer, Inc. Class A Common Stock's next earnings report?
Based on 3
analysts, Seer, Inc. Class A Common Stock is expected to report EPS of -$0.32 and revenue of $4.69M for Q4 2025.